Akouos, Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2020 | $105 M | No. 3 | $50 to $250 million | equity | SEC | |
| Jul 2018 | $25 M | No. 2 | $10 to $50 million | equity | SEC | |
| Oct 2017 | $8 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Akouos, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).
SEC Form D · Mar 2020
The industry group it chose in its notices: Biotechnology.
SEC Form D · Mar 2020
That is all the official record says: Akouos, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
24 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 5AM Opportunities I (GP), LLC | Other | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| 5AM Opportunities I, L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| 5AM Partners V, LLC | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| 5AM Ventures V, L.P. | Venture capital | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Asset Management, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Global Healthcare Master Fund, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Cormorant Private Healthcare Fund II, LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| EcoR1 Capital, LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Emmanuel Simons | Person | not stated | not stated | Held Series SEED-1 preferred stock, 10% owner, director (Form 3, 2020) | SEC Form 3 |
| Marshfield Advisers LLC | Other | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Nea 16 GP, LLC | Other | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| NEA Partners 16, L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| New Enterprise Associates 16, L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Novartis AG | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Novartis Bioventures Ltd | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Partners Innovation Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Partners Innovation Fund, LLC | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pivotal bioVenture Partners Fund I G.P., L.P. | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Pivotal bioVenture Partners Fund I, L.P. | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| RA Capital Nexus Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Sofinnova Management X, L.L.C. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Sofinnova Venture Partners X, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 33 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Aninda Katragadda | Executive officer | Mar 2020 |
| Emmanuel Simons | Executive officer | Mar 2020 |
| Karoline Shair | Executive officer | Mar 2020 |
| Arthur Tzianabos | Director | Mar 2020 |
| Chris Smith | Director | Mar 2020 |
| Ed Mathers | Director | Mar 2020 |
| Emmanuel Simons | Director | Mar 2020 |
| Heather Preston | Director | Mar 2020 |
| Kush Parmar | Director | Mar 2020 |
| Vicki Sato | Director | Mar 2020 |